Avita Medical Ltd (RCEL)


Avita Medical Ltd is a healthcare company focused on therapeutic acute wound care. The company develops and commercializes the RECELL System, a cell-harvesting device used in the treatment of thermal burn wounds and full-thickness skin defects, and for repigmenting stable depigmented vitiligo lesions. Its product range also includes the RECALL autologous cell harvesting device, RECELL autologous cell harvesting devices designed for easier use, and the RECELL GO line for smaller wound areas. In addition, Avita Medical sells PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a collagen-based dermal matrix. The company serves hospitals, treatment centers, and distributors across the United States, Japan, the European Union, Australia, and the United Kingdom. Headquartered in Valencia, California, it was formerly known as AVITA Therapeutics, Inc. before adopting its current name in December 2020.


Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-RCEL
$5.25
0.3% Upside
Fair
$9.10
73.9% Upside
Bargain
Fair
0.0%
August 6, 2026
-3.6x
-7.0x
2.2x
158.2 M
195.5 M
23.3%
98.4%
-13.6
70.1%
Valuation • Fair Value

Avita Medical Ltd (NASDAQ-RCEL) Fair Value by Valuation Model

Compare the primary fair value estimate for Avita Medical Ltd (NASDAQ-RCEL) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$5.25

Estimated upside of 0.3% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$5.18

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$3.21

Earnings power value estimate.

Comps Fair Value

$5.65

Comparable-company valuation reference.

Analyst Price Target

$9.10

Analysts imply upside of 73.9%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Avita Medical Ltd (NASDAQ-RCEL) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Avita Medical Ltd (NASDAQ-RCEL)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

72.347 M

Current operating scale indicator.

Revenue Forecast

81.972 M

Forward revenue estimate.

EBITDA

-37.11 M

Current operating profitability reference.

EBITDA Forecast

-25.305 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Avita Medical Ltd (NASDAQ-RCEL) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Avita Medical Ltd (NASDAQ-RCEL)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

-4.19

No elevated caution signal from this screen.

Altman Z-Score

-13.6

Lower score that deserves closer risk review.

FCF / Net Income

70.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Avita Medical Ltd (NASDAQ-RCEL). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Avita Medical Ltd (NASDAQ-RCEL)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 6, 2026

Days to Earnings

16

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Avita Medical Ltd (NASDAQ-RCEL), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Avita Medical Ltd (NASDAQ-RCEL) Stock Forecast & Technical Outlook

Review Avita Medical Ltd (NASDAQ-RCEL) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Avita Medical Ltd (NASDAQ-RCEL) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Avita Medical Ltd (NASDAQ-RCEL) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Avita Medical Ltd (NASDAQ-RCEL) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Avita Medical Ltd (NASDAQ-RCEL) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Avita Medical Ltd (NASDAQ-RCEL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Avita Medical Ltd (NASDAQ-RCEL)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Avita Medical Ltd (NASDAQ-RCEL) has a Buy consensus, with 2 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 1
Sell 0
FAQ Fast Investor Answers

Avita Medical Ltd (NASDAQ-RCEL) Stock FAQ

Quick answers about Avita Medical Ltd (NASDAQ-RCEL) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$5.25
Estimated upside 0.3%
Valuation Rating
Near Fair Value
Price is close to fair value
Analyst Target
$9.10
Implied upside 73.9%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Avita Medical Ltd (NASDAQ-RCEL) is $5.25. This implies an estimated upside of 0.3% versus the current market price.

Based on the current fair value estimate, the stock is trading close to its estimated fair value.

The available analyst price target for Avita Medical Ltd (NASDAQ-RCEL) is $9.10. The analyst target implies estimated upside of 73.9%.

The current financial health read for Avita Medical Ltd (NASDAQ-RCEL) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Avita Medical Ltd (NASDAQ-RCEL) is August 6, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Avita Medical Ltd (NASDAQ-RCEL) is -3.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Avita Medical Ltd is 158.2 M.

The current enterprise value listed for Avita Medical Ltd is 195.5 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Avita Medical Ltd is NASDAQ-RCEL, and the stock is listed on NASDAQ.

Avita Medical Ltd (NASDAQ-RCEL) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Avita Medical Ltd is 23.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Avita Medical Ltd is 98.4%. Free float helps investors understand how much of the share base is available for public trading.